| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 43 | 2024 | 984 | 3.500 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 13 | 2017 | 264 | 1.150 |
Why?
|
| Cystic Fibrosis | 5 | 2022 | 115 | 1.080 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2021 | 270 | 0.740 |
Why?
|
| Adrenergic beta-Agonists | 4 | 2013 | 74 | 0.630 |
Why?
|
| Anti-Asthmatic Agents | 4 | 2014 | 78 | 0.630 |
Why?
|
| Bronchoalveolar Lavage Fluid | 6 | 2017 | 127 | 0.620 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2018 | 56 | 0.610 |
Why?
|
| Aminophenols | 1 | 2018 | 4 | 0.610 |
Why?
|
| Benzodioxoles | 1 | 2018 | 14 | 0.600 |
Why?
|
| Aminopyridines | 1 | 2018 | 40 | 0.590 |
Why?
|
| Quinolones | 1 | 2018 | 56 | 0.590 |
Why?
|
| Bronchodilator Agents | 5 | 2021 | 66 | 0.530 |
Why?
|
| Bronchi | 8 | 2015 | 230 | 0.500 |
Why?
|
| Nasal Mucosa | 9 | 2024 | 191 | 0.480 |
Why?
|
| Glucocorticoids | 4 | 2019 | 357 | 0.470 |
Why?
|
| DNA Methylation | 5 | 2024 | 666 | 0.460 |
Why?
|
| Bronchiectasis | 3 | 2024 | 15 | 0.450 |
Why?
|
| Hospitalization | 8 | 2024 | 888 | 0.410 |
Why?
|
| Adult | 52 | 2024 | 26822 | 0.380 |
Why?
|
| Patient Education as Topic | 5 | 2016 | 364 | 0.380 |
Why?
|
| Patient Selection | 3 | 2021 | 682 | 0.380 |
Why?
|
| Health Care Coalitions | 1 | 2011 | 9 | 0.370 |
Why?
|
| Community Health Planning | 1 | 2011 | 21 | 0.370 |
Why?
|
| Administration, Inhalation | 10 | 2021 | 192 | 0.370 |
Why?
|
| Salmeterol Xinafoate | 2 | 2021 | 16 | 0.370 |
Why?
|
| Fluticasone | 2 | 2021 | 30 | 0.360 |
Why?
|
| Humidity | 10 | 2008 | 91 | 0.360 |
Why?
|
| Muscle, Smooth | 6 | 2015 | 355 | 0.360 |
Why?
|
| Male | 59 | 2024 | 42680 | 0.350 |
Why?
|
| Forced Expiratory Volume | 8 | 2018 | 126 | 0.350 |
Why?
|
| Mitogens | 3 | 1999 | 62 | 0.330 |
Why?
|
| Humans | 76 | 2024 | 89968 | 0.330 |
Why?
|
| Female | 56 | 2024 | 46594 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2020 | 108 | 0.320 |
Why?
|
| Lung | 10 | 2017 | 1292 | 0.310 |
Why?
|
| Small-Area Analysis | 1 | 2007 | 8 | 0.300 |
Why?
|
| Microbiota | 3 | 2019 | 407 | 0.290 |
Why?
|
| Respiratory System | 2 | 2019 | 117 | 0.290 |
Why?
|
| Middle Aged | 35 | 2024 | 26148 | 0.280 |
Why?
|
| Hyperoxia | 3 | 1995 | 35 | 0.270 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2015 | 346 | 0.270 |
Why?
|
| Metered Dose Inhalers | 3 | 2016 | 33 | 0.260 |
Why?
|
| Urban Health | 2 | 2011 | 56 | 0.260 |
Why?
|
| Epigenesis, Genetic | 3 | 2022 | 521 | 0.260 |
Why?
|
| Chicago | 8 | 2019 | 1434 | 0.250 |
Why?
|
| Health Status Disparities | 1 | 2007 | 191 | 0.250 |
Why?
|
| Hot Temperature | 7 | 2008 | 207 | 0.250 |
Why?
|
| HLA-G Antigens | 2 | 2017 | 52 | 0.240 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2024 | 9 | 0.230 |
Why?
|
| Air | 6 | 2008 | 62 | 0.230 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2024 | 27 | 0.230 |
Why?
|
| Eosinophils | 3 | 2019 | 194 | 0.230 |
Why?
|
| Smoking | 3 | 2017 | 625 | 0.220 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2016 | 57 | 0.220 |
Why?
|
| Catheter Ablation | 3 | 2015 | 254 | 0.220 |
Why?
|
| Nose | 4 | 2008 | 94 | 0.220 |
Why?
|
| Hypersensitivity, Immediate | 3 | 2019 | 63 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2021 | 2362 | 0.210 |
Why?
|
| MicroRNAs | 2 | 2021 | 556 | 0.210 |
Why?
|
| Biomedical Research | 2 | 2019 | 405 | 0.210 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 1452 | 0.210 |
Why?
|
| Nasal Cavity | 5 | 2004 | 91 | 0.200 |
Why?
|
| Interleukin-33 | 1 | 2021 | 27 | 0.190 |
Why?
|
| Neutrophils | 4 | 2019 | 311 | 0.190 |
Why?
|
| Child | 11 | 2022 | 7244 | 0.190 |
Why?
|
| Otolaryngology | 1 | 2022 | 55 | 0.190 |
Why?
|
| Pharmacogenomic Testing | 1 | 2021 | 95 | 0.180 |
Why?
|
| Gene Expression Regulation | 4 | 2024 | 1983 | 0.180 |
Why?
|
| Reproducibility of Results | 5 | 2021 | 2767 | 0.180 |
Why?
|
| Epithelial Cells | 4 | 2021 | 689 | 0.180 |
Why?
|
| Social Class | 1 | 2021 | 137 | 0.180 |
Why?
|
| Spirometry | 3 | 2017 | 68 | 0.170 |
Why?
|
| Adolescent | 12 | 2021 | 9342 | 0.170 |
Why?
|
| Health Planning | 1 | 1999 | 17 | 0.170 |
Why?
|
| Minority Groups | 1 | 2021 | 147 | 0.170 |
Why?
|
| Registries | 1 | 2024 | 808 | 0.170 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 23 | 0.170 |
Why?
|
| Electronic Prescribing | 1 | 2019 | 11 | 0.170 |
Why?
|
| Cross-Sectional Studies | 8 | 2017 | 1730 | 0.170 |
Why?
|
| Sinusitis | 1 | 2022 | 216 | 0.160 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2021 | 284 | 0.160 |
Why?
|
| Aged | 18 | 2024 | 19254 | 0.160 |
Why?
|
| Fungi | 1 | 2019 | 66 | 0.160 |
Why?
|
| Bronchoscopy | 4 | 2015 | 162 | 0.150 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 294 | 0.150 |
Why?
|
| Th2 Cells | 1 | 2019 | 147 | 0.150 |
Why?
|
| Epistasis, Genetic | 1 | 2019 | 90 | 0.150 |
Why?
|
| Child, Preschool | 7 | 2019 | 3773 | 0.150 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 538 | 0.150 |
Why?
|
| Interleukin-6 | 1 | 2019 | 262 | 0.150 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 84 | 0.140 |
Why?
|
| Gene Expression | 2 | 2018 | 1309 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 841 | 0.140 |
Why?
|
| Sputum | 2 | 2017 | 35 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 244 | 0.140 |
Why?
|
| Respiratory System Agents | 1 | 2016 | 7 | 0.130 |
Why?
|
| Self Care | 3 | 2016 | 166 | 0.130 |
Why?
|
| Sleep Wake Disorders | 1 | 2017 | 118 | 0.130 |
Why?
|
| Smokers | 1 | 2016 | 46 | 0.130 |
Why?
|
| United States | 10 | 2024 | 7108 | 0.130 |
Why?
|
| Intention | 1 | 2016 | 51 | 0.130 |
Why?
|
| Bacteria | 2 | 2017 | 486 | 0.130 |
Why?
|
| Cross-Over Studies | 8 | 2019 | 387 | 0.130 |
Why?
|
| Community Health Workers | 2 | 2006 | 33 | 0.130 |
Why?
|
| Patient Compliance | 1 | 2016 | 230 | 0.120 |
Why?
|
| CpG Islands | 3 | 2022 | 158 | 0.120 |
Why?
|
| Genome-Wide Association Study | 2 | 2022 | 1691 | 0.120 |
Why?
|
| International Classification of Diseases | 2 | 2014 | 69 | 0.120 |
Why?
|
| Membrane Proteins | 2 | 2020 | 1227 | 0.120 |
Why?
|
| Prednisone | 1 | 2015 | 255 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 1999 | 437 | 0.120 |
Why?
|
| Pentoxifylline | 1 | 1994 | 7 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 3 | 2014 | 1054 | 0.120 |
Why?
|
| Pregnenediones | 1 | 2014 | 8 | 0.120 |
Why?
|
| Body Temperature | 3 | 2005 | 125 | 0.120 |
Why?
|
| Air Pressure | 1 | 1994 | 7 | 0.120 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2014 | 17 | 0.120 |
Why?
|
| Cholecalciferol | 1 | 2014 | 35 | 0.110 |
Why?
|
| Pseudomonas Infections | 1 | 2014 | 99 | 0.110 |
Why?
|
| Young Adult | 7 | 2021 | 6410 | 0.110 |
Why?
|
| Disease Progression | 2 | 2024 | 1469 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2021 | 2415 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2017 | 351 | 0.110 |
Why?
|
| Quality of Life | 3 | 2022 | 1682 | 0.110 |
Why?
|
| Vitamins | 1 | 2014 | 83 | 0.110 |
Why?
|
| Adalimumab | 1 | 2014 | 89 | 0.110 |
Why?
|
| Smoking Cessation | 1 | 2016 | 258 | 0.110 |
Why?
|
| Respiratory Mechanics | 1 | 1994 | 102 | 0.110 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 205 | 0.110 |
Why?
|
| Phenotype | 4 | 2022 | 2458 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 104 | 0.110 |
Why?
|
| Health Education | 2 | 2006 | 105 | 0.100 |
Why?
|
| Patient Care Management | 1 | 2012 | 30 | 0.100 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2019 | 251 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2013 | 91 | 0.100 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 53 | 0.100 |
Why?
|
| Nasal Provocation Tests | 3 | 2001 | 129 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 2 | 2014 | 798 | 0.100 |
Why?
|
| Trachea | 3 | 1999 | 292 | 0.100 |
Why?
|
| Chest Wall Oscillation | 1 | 2011 | 5 | 0.100 |
Why?
|
| Obesity | 1 | 2018 | 972 | 0.100 |
Why?
|
| Skin Temperature | 2 | 2003 | 15 | 0.100 |
Why?
|
| Clinical Coding | 1 | 2011 | 24 | 0.090 |
Why?
|
| Community Pharmacy Services | 1 | 2011 | 5 | 0.090 |
Why?
|
| Drug Utilization Review | 1 | 2011 | 14 | 0.090 |
Why?
|
| Academic Medical Centers | 2 | 2011 | 384 | 0.090 |
Why?
|
| Cytokines | 3 | 2021 | 811 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2014 | 584 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 6 | 1995 | 1237 | 0.090 |
Why?
|
| Equipment Failure | 1 | 2011 | 122 | 0.090 |
Why?
|
| Air Pollution, Indoor | 1 | 2011 | 64 | 0.090 |
Why?
|
| Quantitative Trait Loci | 3 | 2020 | 615 | 0.090 |
Why?
|
| Postoperative Complications | 2 | 2015 | 2314 | 0.090 |
Why?
|
| Patient Participation | 1 | 2012 | 226 | 0.090 |
Why?
|
| Case-Control Studies | 4 | 2024 | 1867 | 0.080 |
Why?
|
| Rhinitis, Allergic, Seasonal | 5 | 2001 | 179 | 0.080 |
Why?
|
| Inflammation | 1 | 2015 | 981 | 0.080 |
Why?
|
| Inpatients | 1 | 2012 | 312 | 0.080 |
Why?
|
| Health Services Research | 1 | 2010 | 138 | 0.080 |
Why?
|
| Prevalence | 3 | 2011 | 1250 | 0.080 |
Why?
|
| Cell Division | 4 | 1999 | 692 | 0.080 |
Why?
|
| Acute Disease | 4 | 2012 | 846 | 0.080 |
Why?
|
| Prospective Studies | 6 | 2019 | 4331 | 0.080 |
Why?
|
| Genotype | 3 | 2020 | 1853 | 0.080 |
Why?
|
| Phenoxybenzamine | 2 | 2005 | 15 | 0.080 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2005 | 32 | 0.080 |
Why?
|
| Airway Obstruction | 1 | 2009 | 109 | 0.080 |
Why?
|
| Foot | 3 | 2003 | 52 | 0.080 |
Why?
|
| Perception | 1 | 2009 | 179 | 0.070 |
Why?
|
| Risk Factors | 3 | 2022 | 5559 | 0.070 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2008 | 52 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 6783 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2018 | 2887 | 0.070 |
Why?
|
| Double-Blind Method | 4 | 2019 | 1714 | 0.070 |
Why?
|
| Linear Models | 3 | 2017 | 421 | 0.070 |
Why?
|
| Rats | 6 | 1995 | 4048 | 0.070 |
Why?
|
| Vital Capacity | 2 | 2017 | 69 | 0.070 |
Why?
|
| Risk-Taking | 1 | 2007 | 155 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2007 | 216 | 0.070 |
Why?
|
| Mutation | 1 | 2018 | 4168 | 0.070 |
Why?
|
| Water | 2 | 2005 | 286 | 0.070 |
Why?
|
| Incidence | 3 | 2012 | 1603 | 0.070 |
Why?
|
| Algorithms | 2 | 2011 | 1913 | 0.060 |
Why?
|
| Cells, Cultured | 4 | 1999 | 2887 | 0.060 |
Why?
|
| Olfactory Mucosa | 1 | 2005 | 33 | 0.060 |
Why?
|
| Health Status Indicators | 1 | 2005 | 103 | 0.060 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2024 | 10 | 0.060 |
Why?
|
| Ipratropium | 2 | 2003 | 18 | 0.060 |
Why?
|
| Medicaid | 1 | 2007 | 242 | 0.060 |
Why?
|
| Research | 1 | 2005 | 251 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 983 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1929 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2004 | 94 | 0.060 |
Why?
|
| Budesonide | 1 | 2004 | 46 | 0.060 |
Why?
|
| Drug Prescriptions | 1 | 2005 | 141 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 1862 | 0.060 |
Why?
|
| Rhinitis, Allergic, Perennial | 2 | 2001 | 81 | 0.060 |
Why?
|
| Fibronectins | 1 | 2024 | 101 | 0.060 |
Why?
|
| Cell Movement | 2 | 1999 | 786 | 0.050 |
Why?
|
| Protein C | 1 | 2003 | 5 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2006 | 334 | 0.050 |
Why?
|
| Logistic Models | 2 | 2017 | 1214 | 0.050 |
Why?
|
| Mothers | 2 | 2022 | 145 | 0.050 |
Why?
|
| Reflex | 1 | 2003 | 80 | 0.050 |
Why?
|
| Recurrence | 3 | 2011 | 1145 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2014 | 278 | 0.050 |
Why?
|
| Temperature | 2 | 2001 | 409 | 0.050 |
Why?
|
| In Vitro Techniques | 2 | 1995 | 996 | 0.050 |
Why?
|
| Cell Count | 2 | 1999 | 199 | 0.050 |
Why?
|
| Adult Children | 1 | 2022 | 12 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2022 | 34 | 0.050 |
Why?
|
| Bronchial Provocation Tests | 2 | 1999 | 25 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2007 | 608 | 0.050 |
Why?
|
| Japan | 1 | 2022 | 304 | 0.050 |
Why?
|
| Emergency Medical Services | 1 | 2005 | 244 | 0.050 |
Why?
|
| Allergens | 2 | 2000 | 183 | 0.050 |
Why?
|
| Asthma, Exercise-Induced | 1 | 2001 | 6 | 0.050 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2021 | 19 | 0.050 |
Why?
|
| Supine Position | 1 | 2001 | 30 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2024 | 848 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2005 | 436 | 0.050 |
Why?
|
| Ceftizoxime | 1 | 2001 | 3 | 0.050 |
Why?
|
| Platelet-Derived Growth Factor | 3 | 1999 | 66 | 0.050 |
Why?
|
| Histamine | 1 | 2001 | 126 | 0.050 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2021 | 20 | 0.050 |
Why?
|
| Transcriptome | 2 | 2017 | 661 | 0.050 |
Why?
|
| Gene Regulatory Networks | 1 | 2024 | 310 | 0.050 |
Why?
|
| Ribonucleases | 1 | 2001 | 93 | 0.050 |
Why?
|
| Hemolysis | 1 | 2001 | 64 | 0.050 |
Why?
|
| Oxygen | 3 | 1995 | 745 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 1008 | 0.050 |
Why?
|
| Animals | 9 | 2021 | 27528 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2004 | 398 | 0.050 |
Why?
|
| Infant | 3 | 2019 | 3191 | 0.040 |
Why?
|
| Antigens | 1 | 2001 | 229 | 0.040 |
Why?
|
| Body Temperature Regulation | 1 | 2000 | 56 | 0.040 |
Why?
|
| Reaction Time | 1 | 2001 | 311 | 0.040 |
Why?
|
| Phosphorylation | 2 | 1999 | 1130 | 0.040 |
Why?
|
| Geography | 1 | 2021 | 227 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 366 | 0.040 |
Why?
|
| Consumer Health Informatics | 1 | 2019 | 3 | 0.040 |
Why?
|
| Cyclin D1 | 1 | 1999 | 84 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 785 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 203 | 0.040 |
Why?
|
| Organ Transplantation | 1 | 2003 | 283 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 206 | 0.040 |
Why?
|
| Molecular Weight | 2 | 1999 | 331 | 0.040 |
Why?
|
| Sepsis | 1 | 2003 | 329 | 0.040 |
Why?
|
| Administration, Intranasal | 3 | 2005 | 139 | 0.040 |
Why?
|
| Zebrafish | 1 | 2021 | 322 | 0.040 |
Why?
|
| Comorbidity | 1 | 2022 | 953 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 1999 | 226 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 1999 | 98 | 0.040 |
Why?
|
| Chromatin | 1 | 2021 | 403 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2020 | 477 | 0.040 |
Why?
|
| Focus Groups | 1 | 2019 | 177 | 0.040 |
Why?
|
| Forecasting | 1 | 1999 | 304 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2021 | 961 | 0.040 |
Why?
|
| Alleles | 1 | 2021 | 1139 | 0.040 |
Why?
|
| Health Information Exchange | 1 | 2017 | 12 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1576 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1999 | 306 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2012 | 785 | 0.040 |
Why?
|
| Metabolome | 1 | 2017 | 51 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2017 | 86 | 0.030 |
Why?
|
| Self Administration | 1 | 2016 | 72 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2017 | 145 | 0.030 |
Why?
|
| Respiratory Sounds | 1 | 2016 | 34 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 179 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2017 | 244 | 0.030 |
Why?
|
| Cough | 1 | 2016 | 55 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2016 | 91 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 195 | 0.030 |
Why?
|
| Dyspnea | 1 | 2016 | 76 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 614 | 0.030 |
Why?
|
| Survival Analysis | 1 | 1999 | 1498 | 0.030 |
Why?
|
| Checklist | 1 | 2016 | 64 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2017 | 280 | 0.030 |
Why?
|
| Hand Strength | 1 | 1995 | 52 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2019 | 2499 | 0.030 |
Why?
|
| Health Literacy | 1 | 2016 | 73 | 0.030 |
Why?
|
| Eosinophilia | 1 | 2015 | 84 | 0.030 |
Why?
|
| RNA, Bacterial | 1 | 2015 | 111 | 0.030 |
Why?
|
| Equipment Design | 1 | 2016 | 422 | 0.030 |
Why?
|
| Urban Population | 2 | 2006 | 225 | 0.030 |
Why?
|
| Biopsy | 2 | 2015 | 1184 | 0.030 |
Why?
|
| Firearms | 1 | 1995 | 69 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 682 | 0.030 |
Why?
|
| S Phase | 1 | 1994 | 63 | 0.030 |
Why?
|
| Tantalum | 1 | 1994 | 5 | 0.030 |
Why?
|
| Poverty | 2 | 2006 | 183 | 0.030 |
Why?
|
| Surface Tension | 1 | 1994 | 8 | 0.030 |
Why?
|
| 1,2-Dipalmitoylphosphatidylcholine | 1 | 1994 | 9 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2019 | 1102 | 0.030 |
Why?
|
| Bronchial Hyperreactivity | 1 | 1994 | 77 | 0.030 |
Why?
|
| Child Development | 1 | 1995 | 169 | 0.030 |
Why?
|
| Genome, Human | 1 | 2019 | 791 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 450 | 0.030 |
Why?
|
| Macrolides | 1 | 2013 | 30 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 1995 | 165 | 0.030 |
Why?
|
| Fatigue | 1 | 2014 | 174 | 0.030 |
Why?
|
| Exercise Therapy | 1 | 2013 | 82 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2012 | 9210 | 0.030 |
Why?
|
| Analysis of Variance | 3 | 2001 | 899 | 0.030 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2012 | 19 | 0.030 |
Why?
|
| Airway Management | 1 | 2013 | 46 | 0.030 |
Why?
|
| Mental Health | 1 | 2014 | 180 | 0.030 |
Why?
|
| Maternal Exposure | 1 | 2013 | 58 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2014 | 332 | 0.030 |
Why?
|
| Psychometrics | 1 | 2014 | 330 | 0.030 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2012 | 7 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 866 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 667 | 0.030 |
Why?
|
| Respiratory Mucosa | 1 | 2013 | 88 | 0.030 |
Why?
|
| Patient Advocacy | 1 | 2012 | 53 | 0.030 |
Why?
|
| Time Factors | 3 | 2014 | 5359 | 0.030 |
Why?
|
| Immersion | 2 | 2003 | 21 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2012 | 140 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2012 | 59 | 0.020 |
Why?
|
| Radiography | 1 | 1994 | 808 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1995 | 759 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 539 | 0.020 |
Why?
|
| Social Behavior | 1 | 2014 | 300 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 1994 | 1255 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2012 | 171 | 0.020 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2012 | 203 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 210 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 324 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1778 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 435 | 0.020 |
Why?
|
| Respiratory Care Units | 1 | 2009 | 4 | 0.020 |
Why?
|
| Sleep | 1 | 2014 | 455 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 250 | 0.020 |
Why?
|
| Data Collection | 1 | 2011 | 377 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2012 | 958 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2014 | 8273 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2016 | 2327 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2012 | 344 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1396 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2010 | 408 | 0.020 |
Why?
|
| Models, Biological | 1 | 1994 | 1765 | 0.020 |
Why?
|
| Length of Stay | 1 | 2010 | 749 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 1732 | 0.020 |
Why?
|
| Signal Transduction | 1 | 1997 | 3404 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2009 | 326 | 0.020 |
Why?
|
| Housing | 1 | 2006 | 46 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 2655 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2005 | 30 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 3680 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 2 | 1995 | 78 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2006 | 596 | 0.010 |
Why?
|
| Cholinergic Antagonists | 1 | 2003 | 28 | 0.010 |
Why?
|
| Epithelium | 2 | 1994 | 323 | 0.010 |
Why?
|
| Lidocaine | 1 | 2003 | 65 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2003 | 198 | 0.010 |
Why?
|
| Sympathetic Nervous System | 1 | 2003 | 98 | 0.010 |
Why?
|
| Anesthetics, Local | 1 | 2003 | 77 | 0.010 |
Why?
|
| Pancreas Transplantation | 1 | 2003 | 104 | 0.010 |
Why?
|
| Eosinophil Granule Proteins | 1 | 2001 | 20 | 0.010 |
Why?
|
| Atmosphere Exposure Chambers | 1 | 2001 | 7 | 0.010 |
Why?
|
| Nasal Lavage Fluid | 1 | 2001 | 26 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2005 | 1083 | 0.010 |
Why?
|
| Adsorption | 1 | 2001 | 53 | 0.010 |
Why?
|
| Serum Albumin | 1 | 2001 | 128 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2001 | 149 | 0.010 |
Why?
|
| Air Conditioning | 1 | 2001 | 6 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 2001 | 87 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 305 | 0.010 |
Why?
|
| Acoustics | 1 | 2001 | 51 | 0.010 |
Why?
|
| Leukocytes | 1 | 2001 | 209 | 0.010 |
Why?
|
| Random Allocation | 1 | 2001 | 327 | 0.010 |
Why?
|
| Isoantibodies | 1 | 2001 | 120 | 0.010 |
Why?
|
| Skin Tests | 1 | 1999 | 44 | 0.010 |
Why?
|
| Methacholine Chloride | 1 | 1999 | 66 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1999 | 224 | 0.010 |
Why?
|
| Pulmonary Alveoli | 1 | 1999 | 71 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1999 | 103 | 0.010 |
Why?
|
| Colforsin | 1 | 1999 | 74 | 0.010 |
Why?
|
| Nasopharynx | 1 | 1999 | 50 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 1999 | 39 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1999 | 269 | 0.010 |
Why?
|
| Respiration | 1 | 2000 | 267 | 0.010 |
Why?
|
| DNA | 2 | 1995 | 1311 | 0.010 |
Why?
|
| Cattle | 1 | 1999 | 378 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1999 | 696 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1999 | 793 | 0.010 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 1997 | 43 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 2003 | 856 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1995 | 270 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 2003 | 1175 | 0.010 |
Why?
|
| Motor Skills | 1 | 1995 | 79 | 0.010 |
Why?
|
| Blood | 1 | 1995 | 69 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 1994 | 58 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1995 | 103 | 0.010 |
Why?
|
| Airway Resistance | 1 | 1994 | 70 | 0.010 |
Why?
|
| Hypertrophy | 1 | 1994 | 67 | 0.010 |
Why?
|
| Aerosols | 1 | 1994 | 47 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1995 | 114 | 0.010 |
Why?
|
| Acetylcholine | 1 | 1994 | 177 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1994 | 511 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 1995 | 328 | 0.010 |
Why?
|
| Body Weight | 1 | 1994 | 453 | 0.010 |
Why?
|
| Age Factors | 1 | 1994 | 1880 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1995 | 2026 | 0.000 |
Why?
|